<!DOCTYPE html><html lang="en"><head>
    <meta charset="UTF-8"/>
    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
    <title>Leveragen Series A Investor Pitch | The Future of Human Antibody Therapeutics</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400&amp;family=Inter:wght@300;400;500;600&amp;display=swap" rel="stylesheet"/>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css"/>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <style>
        :root {
            --primary: #1e3a5f;
            --secondary: #2d5a87;
            --accent: #4a90a4;
            --highlight: #f8fafb;
            --text-primary: #1a1a1a;
            --text-secondary: #666666;
        }
        
        body {
            font-family: 'Inter', sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            overflow-x: hidden;
        }
        
        .serif {
            font-family: 'Playfair Display', serif;
        }
        
        .toc-fixed {
            position: fixed;
            top: 0;
            left: 0;
            width: 280px;
            height: 100vh;
            background: white;
            border-right: 1px solid #e5e7eb;
            overflow-y: auto;
            z-index: 50;
            padding: 2rem 1.5rem;
        }
        
        .main-content {
            margin-left: 280px;
            min-height: 100vh;
        }
        
        .hero-grid {
            display: grid;
            grid-template-columns: 2fr 1fr;
            gap: 2rem;
            align-items: center;
            min-height: 70vh;
        }
        
        .citation {
            display: inline-block;
            background: var(--accent);
            color: white;
            padding: 2px 6px;
            border-radius: 3px;
            text-decoration: none;
            font-size: 0.75rem;
            font-weight: 600;
            margin-left: 2px;
        }
        
        .citation:hover {
            background: var(--secondary);
        }
        
        .section-divider {
            height: 1px;
            background: linear-gradient(to right, transparent, var(--accent), transparent);
            margin: 4rem 0;
        }
        
        .pull-quote {
            border-left: 4px solid var(--accent);
            padding-left: 2rem;
            font-style: italic;
            font-size: 1.25rem;
            color: var(--text-secondary);
            margin: 2rem 0;
        }
        
        .mermaid-container {
            display: flex;
            justify-content: center;
            min-height: 300px;
            max-height: 800px;
            background: #ffffff;
            border: 2px solid #e5e7eb;
            border-radius: 12px;
            padding: 30px;
            margin: 30px 0;
            box-shadow: 0 8px 25px rgba(0, 0, 0, 0.08);
            position: relative;
            overflow: hidden;
        }

        .mermaid-container .mermaid {
            width: 100%;
            max-width: 100%;
            height: 100%;
            cursor: grab;
            transition: transform 0.3s ease;
            transform-origin: center center;
            display: flex;
            justify-content: center;
            align-items: center;
            touch-action: none;
            -webkit-user-select: none;
            -moz-user-select: none;
            -ms-user-select: none;
            user-select: none;
        }

        .mermaid-container .mermaid svg {
            max-width: 100%;
            height: 100%;
            display: block;
            margin: 0 auto;
        }

        .mermaid-container .mermaid:active {
            cursor: grabbing;
        }

        .mermaid-container.zoomed .mermaid {
            height: 100%;
            width: 100%;
            cursor: grab;
        }

        .mermaid-controls {
            position: absolute;
            top: 15px;
            right: 15px;
            display: flex;
            gap: 10px;
            z-index: 20;
            background: rgba(255, 255, 255, 0.95);
            padding: 8px;
            border-radius: 8px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.1);
        }

        .mermaid-control-btn {
            background: #ffffff;
            border: 1px solid #d1d5db;
            border-radius: 6px;
            padding: 10px;
            cursor: pointer;
            transition: all 0.2s ease;
            color: #374151;
            font-size: 14px;
            min-width: 36px;
            height: 36px;
            text-align: center;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .mermaid-control-btn:hover {
            background: #f8fafc;
            border-color: #3b82f6;
            color: #3b82f6;
            transform: translateY(-1px);
        }

        .mermaid-control-btn:active {
            transform: scale(0.95);
        }
        
@media (max-width: 1024px) {
    .toc-fixed {
        display: none;
    }
    .main-content {
        margin-left: 0;
    }
    .hero-grid {
        grid-template-columns: 1fr;
    }
    .mermaid-control-btn:not(.reset-zoom) {
        display: none;
    }
    .mermaid-controls {
        top: auto;
        bottom: 15px;
        right: 15px;
    }
}

/* Adjustments for small screens (max-width: 768px) */
@media (max-width: 768px) {
    .hero-grid {
        min-height: auto;
        padding: 1rem 0;
    }
    
    section {
        padding-left: 1rem;
        padding-right: 1rem;
    }
    
    .hero-grid h1 {
        font-size: 2.5rem;
    }
    
    .hero-grid p {
        font-size: 1.1rem;
    }
}
    </style>
  </head>

  <body class="bg-white">
    <!-- Fixed Table of Contents -->
    <nav class="toc-fixed">
      <h3 class="serif text-xl font-bold text-gray-800 mb-6">Contents</h3>
      <ul class="space-y-3 text-sm">
        <li>
          <a href="#problem" class="text-gray-600 hover:text-blue-600 transition-colors">1. The Problem</a>
        </li>
        <li class="ml-4">
          <a href="#market-boom" class="text-gray-500 hover:text-blue-600 transition-colors">1.1 Market Boom &amp; Risks</a>
        </li>
        <li class="ml-4">
          <a href="#critical-flaw" class="text-gray-500 hover:text-blue-600 transition-colors">1.2 Critical Flaw</a>
        </li>
        <li class="ml-4">
          <a href="#production-botleneck" class="text-gray-500 hover:text-blue-600 transition-colors">1.3 Production Bottleneck</a>
        </li>
        <li>
          <a href="#solution" class="text-gray-600 hover:text-blue-600 transition-colors">2. Our Solution</a>
        </li>
        <li class="ml-4">
          <a href="#singularity-platform" class="text-gray-500 hover:text-blue-600 transition-colors">2.1 Singularity Platform</a>
        </li>
        <li class="ml-4">
          <a href="#scientific-advantage" class="text-gray-500 hover:text-blue-600 transition-colors">2.2 Scientific Advantage</a>
        </li>
        <li class="ml-4">
          <a href="#validation" class="text-gray-500 hover:text-blue-600 transition-colors">2.3 Preclinical Validation</a>
        </li>
        <li>
          <a href="#market-opportunity" class="text-gray-600 hover:text-blue-600 transition-colors">3. Market Opportunity</a>
        </li>
        <li class="ml-4">
          <a href="#market-size" class="text-gray-500 hover:text-blue-600 transition-colors">3.1 Market Size</a>
        </li>
        <li class="ml-4">
          <a href="#competitive-landscape" class="text-gray-500 hover:text-blue-600 transition-colors">3.2 Competitive Landscape</a>
        </li>
        <li class="ml-4">
          <a href="#commercial-advantage" class="text-gray-500 hover:text-blue-600 transition-colors">3.3 Commercial Advantage</a>
        </li>
        <li>
          <a href="#go-to-market" class="text-gray-600 hover:text-blue-600 transition-colors">4. Go-to-Market</a>
        </li>
        <li class="ml-4">
          <a href="#business-model" class="text-gray-500 hover:text-blue-600 transition-colors">4.1 Business Model</a>
        </li>
        <li class="ml-4">
          <a href="#regulatory-path" class="text-gray-500 hover:text-blue-600 transition-colors">4.2 Regulatory Path</a>
        </li>
        <li class="ml-4">
          <a href="#series-a" class="text-gray-500 hover:text-blue-600 transition-colors">4.3 Series A Ask</a>
        </li>
        <li>
          <a href="#team" class="text-gray-600 hover:text-blue-600 transition-colors">5. Team &amp; Vision</a>
        </li>
      </ul>
    </nav>

    <!-- Main Content -->
    <main class="main-content">
      <!-- Hero Section -->
      <section class="bg-gradient-to-br from-slate-50 to-blue-50 px-8 py-16">
        <div class="max-w-7xl mx-auto">
          <div class="hero-grid">
            <div class="space-y-8">
              <div class="space-y-4">
                <h1 class="serif text-5xl lg:text-6xl font-bold text-gray-900 leading-tight">
                  The <em class="text-blue-700">Hidden Risks</em> of the Nanobody Gold Rush
                </h1>
                <p class="text-xl text-gray-600 font-light">
                  How Leveragen&#39;s fully human single-domain antibody platform is positioned to capture the $2.5B market opportunity
                </p>
              </div>

              <div class="grid grid-cols-1 md:grid-cols-3 gap-6 pt-6">
                <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
                  <div class="text-3xl font-bold text-blue-700">$603M</div>
                  <div class="text-sm text-gray-600 mt-1">Nanobody Market 2024</div>
                </div>
                <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
                  <div class="text-3xl font-bold text-blue-700">20.9%</div>
                  <div class="text-sm text-gray-600 mt-1">CAGR to $3.3B by 2033</div>
                </div>
                <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
                  <div class="text-3xl font-bold text-blue-700">$15M</div>
                  <div class="text-sm text-gray-600 mt-1">Series A Investment Ask</div>
                </div>
              </div>
            </div>

            <div class="relative">
              <img src="https://kimi-web-img.moonshot.cn/img/engineering.uci.edu/54a488dc7bd6340e7178f502906ccf5202ffc2c7.png" alt="Laboratory research on antibody engineering" class="rounded-2xl shadow-2xl w-full h-96 object-cover" size="large" aspect="wide" style="photo" query="antibody engineering laboratory research" referrerpolicy="no-referrer" data-modified="1" data-score="0.00"/>
              <div class="absolute inset-0 bg-gradient-to-t from-black/20 to-transparent rounded-2xl"></div>
            </div>
          </div>
        </div>
      </section>

      <!-- Problem Section -->
      <section id="problem" class="px-8 py-16 max-w-6xl mx-auto">
        <h2 class="serif text-4xl font-bold text-gray-900 mb-8">The Problem: The Hidden Risks of the Nanobody Gold Rush</h2>

        <!-- Market Boom -->
        <div id="market-boom" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Llama Nanobody Market is Booming, But...</h3>

          <div class="grid lg:grid-cols-2 gap-8 mb-8">
            <div>
              <p class="text-lg text-gray-700 mb-6">
                The market for single-domain antibodies is experiencing explosive growth, valued at <strong>$568.3 million in 2025</strong> and projected to reach <strong>$2.58 billion by 2032</strong>
                <a href="https://www.coherentmarketinsights.com/market-insight/nanobodies-market-1680" class="citation">209</a>.
                This 24.1% CAGR reflects strong confidence in nanobodies&#39; potential across oncology, autoimmune, and infectious diseases.
              </p>

              <div class="pull-quote">
                &#34;The unique structural advantages of nanobodies allow for better tissue penetration and targeting of cryptic epitopes inaccessible to conventional antibodies.&#34;
              </div>
            </div>

            <div>
              <div class="bg-blue-50 p-6 rounded-lg">
                <h4 class="font-semibold text-gray-800 mb-4">Key Market Players</h4>
                <ul class="space-y-2 text-gray-700">
                  <li><strong>Sanofi/Ablynx:</strong> Market leader through €3.9B acquisition</li>
                  <li><strong>Merck KGaA:</strong> Major pharmaceutical investment</li>
                  <li><strong>GenScript:</strong> Specialized platform development</li>
                  <li><strong>Attovia Therapeutics:</strong> $60M Series A funding</li>
                </ul>
              </div>
            </div>
          </div>
        </div>

        <!-- Critical Flaw -->
        <div id="critical-flaw" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Critical Flaw: Immunogenicity and Humanization Hurdles</h3>

          <div class="bg-red-50 border-l-4 border-red-400 p-6 mb-8">
            <h4 class="font-semibold text-red-800 mb-3">The Immunogenicity Risk</h4>
            <p class="text-red-700">
              Camelid-derived VHHs contain non-human sequences that can trigger anti-drug antibodies (ADAs) in patients. Despite 86-94% homology with human VH3 genes, unique epitopes remain that pose immunogenicity risks <a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.632687/full" class="citation">219</a>.
            </p>
          </div>

          <div class="grid md:grid-cols-2 gap-8 mb-8">
            <div class="space-y-4">
              <h4 class="font-semibold text-gray-800">Case Studies of Failure</h4>
              <div class="space-y-3">
                <div class="bg-gray-50 p-4 rounded">
                  <strong>TAS266:</strong> Tetrameric DR5-specific VHH discontinued due to high immunogenicity
                  <a href="https://pubmed.ncbi.nlm.nih.gov/33751827/" class="citation">218</a>
                </div>
                <div class="bg-gray-50 p-4 rounded">
                  <strong>GSK1995057:</strong> TNFR1-specific VHH faced similar immunogenicity challenges
                  <a href="https://pubmed.ncbi.nlm.nih.gov/33751827/" class="citation">218</a>
                </div>
                <div class="bg-gray-50 p-4 rounded">
                  <strong>Pfizer&#39;s bococizumab:</strong> PCSK9 inhibitor discontinued due to high immunogenicity
                  <a href="https://www.nature.com/articles/s41598-022-16453-3" class="citation">232</a>
                </div>
              </div>
            </div>

            <div class="space-y-4">
              <h4 class="font-semibold text-gray-800">The Humanization Challenge</h4>
              <div class="space-y-3 text-gray-700">
                <p><strong>Complex Process:</strong> Requires 17+ amino acid mutations for humanization</p>
                <p><strong>Affinity Loss:</strong> Complete humanization often leads to decreased binding</p>
                <p><strong>Costly &amp; Time-Consuming:</strong> Extensive optimization required</p>
                <p><strong>No Guarantee:</strong> Humanization doesn&#39;t always eliminate immunogenicity</p>
              </div>
            </div>
          </div>
        </div>

        <!-- Production Bottleneck -->
        <div id="production-botleneck" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Production Bottleneck: Scalability and Cost</h3>

          <div class="grid lg:grid-cols-3 gap-6 mb-8">
            <div class="bg-yellow-50 p-6 rounded-lg">
              <h4 class="font-semibold text-yellow-800 mb-3">Llamas: Slow &amp; Expensive</h4>
              <ul class="text-yellow-700 space-y-2 text-sm">
                <li>• Specialized facilities required</li>
                <li>• 2-3 month immunization timeline</li>
                <li>• High maintenance costs</li>
                <li>• Limited scalability</li>
              </ul>
            </div>

            <div class="bg-orange-50 p-6 rounded-lg">
              <h4 class="font-semibold text-orange-800 mb-3">Complex Discovery Process</h4>
              <ul class="text-orange-700 space-y-2 text-sm">
                <li>• B cell isolation &amp; RNA extraction</li>
                <li>• Phage display library construction</li>
                <li>• Multiple selection rounds</li>
                <li>• Time-consuming optimization</li>
              </ul>
            </div>

            <div class="bg-red-50 p-6 rounded-lg">
              <h4 class="font-semibold text-red-800 mb-3">Manufacturing Challenges</h4>
              <ul class="text-red-700 space-y-2 text-sm">
                <li>• Complex formatting needs</li>
                <li>• Half-life extension requirements</li>
                <li>• Specialized production methods</li>
                <li>• High COGS impact</li>
              </ul>
            </div>
          </div>

          <p class="text-gray-700">
            The traditional approach relying on exotic animal immunization creates significant supply chain vulnerabilities and ethical considerations. Disease outbreaks or regulatory changes could disrupt the entire nanobody industry <a href="https://www.nature.com/articles/s41598-024-68680-5" class="citation">222</a>.
          </p>
        </div>
      </section>

      <div class="section-divider"></div>

      <!-- Solution Section -->
      <section id="solution" class="px-8 py-16 max-w-6xl mx-auto">
        <h2 class="serif text-4xl font-bold text-gray-900 mb-8">Leveragen&#39;s Solution: The First Fully Human Single-Domain Antibody Platform</h2>

        <!-- Singularity Platform -->
        <div id="singularity-platform" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Singularity Mouse™ Platform</h3>

          <div class="grid lg:grid-cols-2 gap-8 mb-8">
            <div>
              <img src="https://kimi-web-img.moonshot.cn/img/www.genome.gov/1491d18d283de7d3a45e6308c46fe50cb86ac16e.jpg" alt="Genetically engineered mouse in laboratory setting" class="rounded-lg shadow-lg w-full h-64 object-cover" size="medium" aspect="wide" style="photo" query="laboratory mouse genetic engineering research" referrerpolicy="no-referrer" data-modified="1" data-score="0.00"/>
            </div>

            <div class="space-y-4">
              <p class="text-lg text-gray-700">
                Leveragen&#39;s proprietary <strong>Singularity Mouse™ platform</strong> represents a paradigm shift in antibody discovery. Using genetically engineered mice humanized to produce fully human single-domain antibodies directly in vivo <a href="https://crisprmedicinenews.com/press-release-service/card/leveragen-and-92bio-forge-strategic-alliance-to-advance-therapeutics-using-novel-single-domain-antib/" class="citation">176</a>.
              </p>

              <div class="bg-green-50 p-4 rounded-lg border border-green-200">
                <h4 class="font-semibold text-green-800 mb-2">Key Innovation</h4>
                <p class="text-green-700 text-sm">
                  Bypasses the critical humanization process entirely, generating 100% human antibodies from discovery through development
                </p>
              </div>

              <div class="space-y-2 text-sm">
                <div class="flex items-center space-x-2">
                  <i class="fas fa-check text-green-500"></i>
                  <span>Leverages natural humoral immune response</span>
                </div>
                <div class="flex items-center space-x-2">
                  <i class="fas fa-check text-green-500"></i>
                  <span>CRISPR-engineered human heavy chain locus</span>
                </div>
                <div class="flex items-center space-x-2">
                  <i class="fas fa-check text-green-500"></i>
                  <span>Next-generation sequencing workflow</span>
                </div>
              </div>
            </div>
          </div>

          <!-- Platform Advantages -->
          <div class="bg-gradient-to-r from-blue-50 to-indigo-50 p-8 rounded-xl">
            <h4 class="serif text-xl font-semibold text-gray-800 mb-6 text-center">Platform Advantages</h4>
            <div class="grid md:grid-cols-3 gap-6">
              <div class="text-center">
                <div class="w-16 h-16 bg-blue-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-shield-alt text-white text-xl"></i>
                </div>
                <h5 class="font-semibold text-gray-800 mb-2">De-Risked</h5>
                <p class="text-sm text-gray-600">Eliminates immunogenicity concerns from non-human sequences</p>
              </div>
              <div class="text-center">
                <div class="w-16 h-16 bg-indigo-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-rocket text-white text-xl"></i>
                </div>
                <h5 class="font-semibold text-gray-800 mb-2">Scalable</h5>
                <p class="text-sm text-gray-600">Leverages predictable and scalable mouse model infrastructure</p>
              </div>
              <div class="text-center">
                <div class="w-16 h-16 bg-purple-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-clock text-white text-xl"></i>
                </div>
                <h5 class="font-semibold text-gray-800 mb-2">Efficient</h5>
                <p class="text-sm text-gray-600">Accelerated discovery through natural in vivo selection</p>
              </div>
            </div>
          </div>
        </div>

        <!-- Scientific Advantage -->
        <div id="scientific-advantage" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Scientific Advantage: A Superior Therapeutic Profile</h3>

          <div class="space-y-8">
            <div class="grid md:grid-cols-3 gap-6">
              <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
                <h4 class="font-semibold text-gray-800 mb-3 flex items-center">
                  <i class="fas fa-dna text-blue-600 mr-2"></i>
                  Eliminated Immunogenicity
                </h4>
                <p class="text-gray-600 text-sm">
                  100% human sequence eliminates anti-drug antibody risks associated with camelid VHHs. No humanization required.
                </p>
              </div>

              <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
                <h4 class="font-semibold text-gray-800 mb-3 flex items-center">
                  <i class="fas fa-crosshairs text-green-600 mr-2"></i>
                  Novel Epitope Access
                </h4>
                <p class="text-gray-600 text-sm">
                  Human-like paratopes enable targeting of challenging proteins like GPCRs and ion channels with high specificity.
                </p>
              </div>

              <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
                <h4 class="font-semibold text-gray-800 mb-3 flex items-center">
                  <i class="fas fa-cube text-purple-600 mr-2"></i>
                  Optimal Stability
                </h4>
                <p class="text-gray-600 text-sm">
                  Human scaffold ensures high solubility and stability, reducing aggregation and manufacturing complexity.
                </p>
              </div>
            </div>

            <div class="pull-quote">
              &#34;By generating antibodies from a human repertoire within a living system, we ensure only well-behaved, properly folded proteins with superior biophysical properties make it to development.&#34;
            </div>
          </div>
        </div>

        <!-- Preclinical Validation -->
        <div id="validation" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">Preclinical Validation and Traction</h3>

          <!-- Success Metrics -->
          <div class="grid md:grid-cols-2 lg:grid-cols-4 gap-6 mb-8">
            <div class="text-center p-6 bg-gradient-to-br from-blue-50 to-blue-100 rounded-xl">
              <div class="text-3xl font-bold text-blue-700 mb-2">20+</div>
              <div class="text-sm text-blue-600">Discovery Campaigns Completed</div>
            </div>
            <div class="text-center p-6 bg-gradient-to-br from-green-50 to-green-100 rounded-xl">
              <div class="text-3xl font-bold text-green-700 mb-2">92Bio</div>
              <div class="text-sm text-green-600">Strategic Partnership</div>
            </div>
            <div class="text-center p-6 bg-gradient-to-br from-purple-50 to-purple-100 rounded-xl">
              <div class="text-3xl font-bold text-purple-700 mb-2">Moderna</div>
              <div class="text-sm text-purple-600">Research Collaboration</div>
            </div>
            <div class="text-center p-6 bg-gradient-to-br from-orange-50 to-orange-100 rounded-xl">
              <div class="text-3xl font-bold text-orange-700 mb-2">15 kDa</div>
              <div class="text-sm text-orange-600">Superior Brain Penetration</div>
            </div>
          </div>

          <!-- Case Studies -->
          <div class="space-y-6">
            <div class="bg-white border border-gray-200 rounded-lg p-6">
              <h4 class="font-semibold text-gray-800 mb-3">Nipah Virus Neutralization Success</h4>
              <p class="text-gray-700 mb-3">
                UdAb n425 demonstrated potent neutralizing activity with superior brain penetrance due to small size (15 kDa). In suckling mouse models, both monomeric and divalent versions showed therapeutic efficacy <a href="https://www.nature.com/articles/s41467-024-51066-6" class="citation">146</a>.
              </p>
              <div class="flex items-center space-x-4 text-sm text-gray-600">
                <span><strong>Key Advantage:</strong> Greater CNS penetration than conventional antibodies</span>
              </div>
            </div>

            <div class="bg-white border border-gray-200 rounded-lg p-6">
              <h4 class="font-semibold text-gray-800 mb-3">Cancer Targeting with SBT-100</h4>
              <p class="text-gray-700 mb-3">
                Bispecific single-domain antibody targeting both KRAS and STAT3 pathways demonstrated potent antiproliferative activity across 11 human cancer cell lines, with growth suppression ranging from 64% to 93% <a href="https://www.nature.com/articles/d43747-021-00093-z" class="citation">164</a>.
              </p>
              <div class="flex items-center space-x-4 text-sm text-gray-600">
                <span><strong>Coverage:</strong> Pancreatic, breast, and prostate cancers</span>
              </div>
            </div>
          </div>
        </div>
      </section>

      <div class="section-divider"></div>

      <!-- Market Opportunity -->
      <section id="market-opportunity" class="px-8 py-16 max-w-6xl mx-auto">
        <h2 class="serif text-4xl font-bold text-gray-900 mb-8">Market Opportunity: Capturing the Next Wave of Antibody Therapeutics</h2>

        <!-- Market Size -->
        <div id="market-size" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Expanding Single-Domain Antibody Market</h3>

          <div class="grid lg:grid-cols-2 gap-8 mb-8">
            <div class="space-y-6">
              <p class="text-lg text-gray-700">
                The global single-domain antibody market presents a compelling growth opportunity, valued at <strong>$603 million in 2024</strong> and projected to reach <strong>$3.3 billion by 2033</strong>, representing a 20.9% compound annual growth rate <a href="https://www.coherentmarketinsights.com/market-insight/nanobodies-market-1680" class="citation">87</a>.
              </p>

              <div class="bg-blue-50 p-6 rounded-lg">
                <h4 class="font-semibold text-blue-800 mb-4">Growth Drivers</h4>
                <ul class="space-y-2 text-blue-700 text-sm">
                  <li>• Superior tissue penetration capabilities</li>
                  <li>• Access to cryptic epitopes</li>
                  <li>• Versatile engineering into multi-specific formats</li>
                  <li>• Expanding therapeutic applications</li>
                </ul>
              </div>
            </div>

            <div>
              <div class="bg-white border border-gray-200 rounded-lg p-6">
                <h4 class="font-semibold text-gray-800 mb-4">Broader Market Context</h4>
                <p class="text-gray-700 text-sm mb-4">
                  The next-generation antibody therapeutics market, including ADCs and bispecifics, is projected to grow from <strong>$9.09 billion in 2024</strong> to <strong>$22.88 billion by 2033</strong>
                  <a href="https://finance.yahoo.com/news/next-generation-antibody-therapeutics-market-140100082.html?fr=sycsrp_catchall" class="citation">181</a>.
                </p>
                <div class="text-center p-4 bg-gray-50 rounded">
                  <div class="text-2xl font-bold text-gray-800">10.9%</div>
                  <div class="text-sm text-gray-600">CAGR for broader antibody market</div>
                </div>
              </div>
            </div>
          </div>
        </div>

        <!-- Competitive Landscape -->
        <div id="competitive-landscape" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Competitive Landscape: A Gap in the Market</h3>

          <div class="mb-8">
            <div class="mermaid-container">
              <div class="mermaid-controls">
                <button class="mermaid-control-btn zoom-in" title="放大">
                  <i class="fas fa-search-plus"></i>
                </button>
                <button class="mermaid-control-btn zoom-out" title="缩小">
                  <i class="fas fa-search-minus"></i>
                </button>
                <button class="mermaid-control-btn reset-zoom" title="重置">
                  <i class="fas fa-expand-arrows-alt"></i>
                </button>
                <button class="mermaid-control-btn fullscreen" title="全屏查看">
                  <i class="fas fa-expand"></i>
                </button>
              </div>
              <div class="mermaid">
                graph TB
                A[&#34;Single-Domain Antibody Market&#34;] --&gt; B[&#34;Llama-Derived VHHs
                <br/>63% Market Share&#34;]
                A --&gt; C[&#34;Synthetic Human Libraries
                <br/>27% Market Share&#34;]
                A --&gt; D[&#34;Leveragen Platform
                <br/>10% Market Opportunity&#34;]

                B --&gt; B1[&#34;Sanofi/Ablynx
                <br/>- High immunogenicity risk
                <br/>- Costly humanization
                <br/>- Production bottlenecks&#34;]
                B --&gt; B2[&#34;Other Players
                <br/>- Attovia
                <br/>- Numab Therapeutics&#34;]

                C --&gt; C1[&#34;Phage Display
                <br/>- Limited affinity
                <br/>- Stability issues
                <br/>- Engineering complexity&#34;]
                C --&gt; C2[&#34;Yeast Display
                <br/>- Developability challenges
                <br/>- Complex target limitations&#34;]

                D --&gt; D1[&#34;Fully Human
                <br/>✓ Zero immunogenicity
                <br/>✓ No humanization needed
                <br/>✓ Scalable mouse model&#34;]
                D --&gt; D2[&#34;In Vivo Selection
                <br/>✓ Natural affinity maturation
                <br/>✓ Superior stability
                <br/>✓ Cost-effective production&#34;]

                style B fill:#ffebee,stroke:#d32f2f,stroke-width:2px,color:#000
                style C fill:#fff3e0,stroke:#f57c00,stroke-width:2px,color:#000
                style D fill:#e8f5e8,stroke:#388e3c,stroke-width:2px,color:#000
                style A fill:#f5f5f5,stroke:#424242,stroke-width:3px,color:#000
                style B1 fill:#ffebee,stroke:#d32f2f,stroke-width:1px,color:#333
                style B2 fill:#ffebee,stroke:#d32f2f,stroke-width:1px,color:#333
                style C1 fill:#fff3e0,stroke:#f57c00,stroke-width:1px,color:#333
                style C2 fill:#fff3e0,stroke:#f57c00,stroke-width:1px,color:#333
                style D1 fill:#e8f5e8,stroke:#388e3c,stroke-width:1px,color:#333
                style D2 fill:#e8f5e8,stroke:#388e3c,stroke-width:1px,color:#333
              </div>
            </div>
          </div>

          <div class="grid lg:grid-cols-3 gap-6">
            <div class="bg-red-50 p-6 rounded-lg border border-red-200">
              <h4 class="font-semibold text-red-800 mb-3">Llama-Derived VHHs</h4>
              <div class="space-y-2 text-red-700 text-sm">
                <div>✗ High immunogenicity risk</div>
                <div>✗ Complex humanization process</div>
                <div>✗ Production scalability issues</div>
                <div>✗ Supply chain vulnerabilities</div>
              </div>
            </div>

            <div class="bg-orange-50 p-6 rounded-lg border border-orange-200">
              <h4 class="font-semibold text-orange-800 mb-3">Synthetic Libraries</h4>
              <div class="space-y-2 text-orange-700 text-sm">
                <div>✗ Limited affinity and stability</div>
                <div>✗ Developability challenges</div>
                <div>✗ Complex target limitations</div>
                <div>✗ Extensive engineering required</div>
              </div>
            </div>

            <div class="bg-green-50 p-6 rounded-lg border border-green-200">
              <h4 class="font-semibold text-green-800 mb-3">Leveragen Platform</h4>
              <div class="space-y-2 text-green-700 text-sm">
                <div>✓ Zero immunogenicity risk</div>
                <div>✓ Natural affinity maturation</div>
                <div>✓ Scalable mouse model</div>
                <div>✓ Cost-effective production</div>
              </div>
            </div>
          </div>
        </div>

        <!-- Commercial Advantage -->
        <div id="commercial-advantage" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The Commercial Advantage: A Clearer Path to the Clinic</h3>

          <div class="space-y-8">
            <div class="grid md:grid-cols-3 gap-6">
              <div class="text-center p-6 bg-gradient-to-b from-blue-50 to-white rounded-xl">
                <div class="w-16 h-16 bg-blue-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-shield-alt text-white text-xl"></i>
                </div>
                <h4 class="font-semibold text-gray-800 mb-3">De-Risked Development</h4>
                <p class="text-gray-600 text-sm">
                  Elimination of immunogenicity increases clinical success probability and reduces costly testing requirements.
                </p>
              </div>

              <div class="text-center p-6 bg-gradient-to-b from-green-50 to-white rounded-xl">
                <div class="w-16 h-16 bg-green-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-fast-forward text-white text-xl"></i>
                </div>
                <h4 class="font-semibold text-gray-800 mb-3">Streamlined Regulatory</h4>
                <p class="text-gray-600 text-sm">
                  Fully human antibodies align with established FDA/EMA guidelines for therapeutic antibodies.
                </p>
              </div>

              <div class="text-center p-6 bg-gradient-to-b from-purple-50 to-white rounded-xl">
                <div class="w-16 h-16 bg-purple-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-industry text-white text-xl"></i>
                </div>
                <h4 class="font-semibold text-gray-800 mb-3">Scalable Manufacturing</h4>
                <p class="text-gray-600 text-sm">
                  Compatible with standard CHO cell production infrastructure and mature manufacturing processes.
                </p>
              </div>
            </div>

            <div class="bg-gradient-to-r from-gray-50 to-blue-50 p-8 rounded-xl">
              <h4 class="font-semibold text-gray-800 mb-4 text-center">Commercial Value Proposition</h4>
              <div class="grid md:grid-cols-2 gap-6">
                <div>
                  <h5 class="font-medium text-gray-800 mb-3">Cost Advantages</h5>
                  <ul class="space-y-2 text-gray-700 text-sm">
                    <li>• No humanization costs ($1-2M per candidate)</li>
                    <li>• Reduced immunogenicity testing complexity</li>
                    <li>• Standard manufacturing infrastructure</li>
                    <li>• Predictable development timelines</li>
                  </ul>
                </div>
                <div>
                  <h5 class="font-medium text-gray-800 mb-3">Value Drivers</h5>
                  <ul class="space-y-2 text-gray-700 text-sm">
                    <li>• Higher probability of clinical success</li>
                    <li>• Attractive to pharma partners</li>
                    <li>• Premium valuation multiples</li>
                    <li>• Broader therapeutic applications</li>
                  </ul>
                </div>
              </div>
            </div>
          </div>
        </div>
      </section>

      <div class="section-divider"></div>

      <!-- Go-to-Market Strategy -->
      <section id="go-to-market" class="px-8 py-16 max-w-6xl mx-auto">
        <h2 class="serif text-4xl font-bold text-gray-900 mb-8">Go-to-Market Strategy and Series A Use of Funds</h2>

        <!-- Business Model -->
        <div id="business-model" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">Business Model: A Platform for Partnership and Pipeline Development</h3>

          <div class="grid lg:grid-cols-2 gap-8 mb-8">
            <div class="space-y-6">
              <p class="text-lg text-gray-700">
                Leveragen&#39;s hybrid business model combines strategic partnerships with internal pipeline development, creating multiple value streams while mitigating single-product risk.
              </p>

              <div class="bg-blue-50 p-6 rounded-lg">
                <h4 class="font-semibold text-blue-800 mb-3">Revenue Streams</h4>
                <div class="space-y-2 text-blue-700 text-sm">
                  <div class="flex items-center space-x-2">
                    <i class="fas fa-handshake text-blue-600"></i>
                    <span><strong>Partnerships:</strong> Upfront payments, milestones, royalties</span>
                  </div>
                  <div class="flex items-center space-x-2">
                    <i class="fas fa-flask text-blue-600"></i>
                    <span><strong>Internal Pipeline:</strong> Full ownership of lead assets</span>
                  </div>
                  <div class="flex items-center space-x-2">
                    <i class="fas fa-cogs text-blue-600"></i>
                    <span><strong>Platform Licensing:</strong> Technology access fees</span>
                  </div>
                </div>
              </div>
            </div>

            <div>
              <img src="https://kimi-web-img.moonshot.cn/img/sharevault.com/baf3ffcf9d19d3945129185bccdf58bf47ac0eb7.jpg" alt="Business partnership handshake in laboratory setting" class="rounded-lg shadow-lg w-full h-64 object-cover" size="medium" aspect="wide" style="photo" query="business partnership handshake laboratory" referrerpolicy="no-referrer" data-modified="1" data-score="0.00"/>
            </div>
          </div>

          <div class="grid md:grid-cols-3 gap-6">
            <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
              <h4 class="font-semibold text-gray-800 mb-3 flex items-center">
                <i class="fas fa-building text-blue-600 mr-2"></i>
                Targeted Partnerships
              </h4>
              <p class="text-gray-600 text-sm mb-3">
                Collaborate with pharma and biotech leaders to leverage their disease expertise and commercial infrastructure.
              </p>
              <div class="text-xs text-gray-500">
                <strong>Current Partners:</strong> 92Bio, Moderna
              </div>
            </div>

            <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
              <h4 class="font-semibold text-gray-800 mb-3 flex items-center">
                <i class="fas fa-rocket text-green-600 mr-2"></i>
                Internal Pipeline
              </h4>
              <p class="text-gray-600 text-sm mb-3">
                Develop proprietary therapeutics in high-value indications: oncology, autoimmune, and infectious diseases.
              </p>
              <div class="text-xs text-gray-500">
                <strong>Focus:</strong> Retain full ownership of key assets
              </div>
            </div>

            <div class="bg-white p-6 rounded-lg shadow-sm border border-gray-200">
              <h4 class="font-semibold text-gray-800 mb-3 flex items-center">
                <i class="fas fa-copyright text-purple-600 mr-2"></i>
                Platform Licensing
              </h4>
              <p class="text-gray-600 text-sm mb-3">
                License Singularity Mouse™ technology to expand reach and validate platform through external applications.
              </p>
              <div class="text-xs text-gray-500">
                <strong>Benefit:</strong> Additional non-dilutive revenue
              </div>
            </div>
          </div>
        </div>

        <!-- Regulatory Path -->
        <div id="regulatory-path" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">Regulatory and Clinical Pathway</h3>

          <div class="bg-gradient-to-r from-blue-50 to-indigo-50 p-8 rounded-xl mb-8">
            <div class="grid md:grid-cols-3 gap-8 text-center">
              <div>
                <div class="w-16 h-16 bg-blue-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-vial text-white text-xl"></i>
                </div>
                <h4 class="font-semibold text-gray-800 mb-2">IND-Enabling Studies</h4>
                <p class="text-gray-600 text-sm">Comprehensive safety, pharmacology, and toxicology evaluation</p>
              </div>

              <div>
                <div class="w-16 h-16 bg-indigo-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-file-medical text-white text-xl"></i>
                </div>
                <h4 class="font-semibold text-gray-800 mb-2">IND Filing</h4>
                <p class="text-gray-600 text-sm">First IND applications within 24 months of Series A closing</p>
              </div>

              <div>
                <div class="w-16 h-16 bg-purple-600 rounded-full flex items-center justify-center mx-auto mb-4">
                  <i class="fas fa-hospital text-white text-xl"></i>
                </div>
                <h4 class="font-semibold text-gray-800 mb-2">Clinical Trials</h4>
                <p class="text-gray-600 text-sm">Leverage established regulatory precedents for human antibodies</p>
              </div>
            </div>
          </div>

          <div class="space-y-4">
            <div class="bg-white border border-gray-200 rounded-lg p-6">
              <h4 class="font-semibold text-gray-800 mb-3">Regulatory Advantages</h4>
              <div class="grid md:grid-cols-2 gap-4">
                <ul class="space-y-2 text-gray-700 text-sm">
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-check text-green-500"></i>
                    <span>Fully human antibodies align with FDA/EMA guidelines</span>
                  </li>
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-check text-green-500"></i>
                    <span>Established safety record for human mAbs</span>
                  </li>
                </ul>
                <ul class="space-y-2 text-gray-700 text-sm">
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-check text-green-500"></i>
                    <span>Simplified toxicology packages</span>
                  </li>
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-check text-green-500"></i>
                    <span>Predictable development timelines</span>
                  </li>
                </ul>
              </div>
            </div>
          </div>
        </div>

        <!-- Series A Ask -->
        <div id="series-a" class="mb-16">
          <h3 class="serif text-2xl font-semibold text-gray-800 mb-6">The $15M Series A Ask</h3>

          <div class="bg-gradient-to-br from-blue-600 to-indigo-700 text-white p-8 rounded-2xl mb-8">
            <div class="text-center mb-6">
              <div class="text-6xl font-bold mb-2">$15M</div>
              <div class="text-xl opacity-90">Series A Financing Round</div>
            </div>

            <div class="grid md:grid-cols-3 gap-6 text-center">
              <div>
                <div class="text-2xl font-bold mb-1">24 Months</div>
                <div class="text-sm opacity-90">To IND Filing</div>
              </div>
              <div>
                <div class="text-2xl font-bold mb-1">3 Programs</div>
                <div class="text-sm opacity-90">Lead Candidates</div>
              </div>
              <div>
                <div class="text-2xl font-bold mb-1">World-Class</div>
                <div class="text-sm opacity-90">Team Building</div>
              </div>
            </div>
          </div>

          <!-- Use of Funds Breakdown -->
          <div class="grid lg:grid-cols-2 gap-8 mb-8">
            <div>
              <h4 class="font-semibold text-gray-800 mb-4">Primary Use of Funds</h4>
              <div class="space-y-4">
                <div class="bg-white border border-gray-200 rounded-lg p-4">
                  <div class="flex justify-between items-center mb-2">
                    <span class="font-medium text-gray-800">IND-Enabling Studies</span>
                    <span class="text-blue-600 font-bold">$7M</span>
                  </div>
                  <p class="text-gray-600 text-sm">
                    Advance lead programs through comprehensive preclinical development, safety assessment, and manufacturing process development.
                  </p>
                </div>

                <div class="bg-white border border-gray-200 rounded-lg p-4">
                  <div class="flex justify-between items-center mb-2">
                    <span class="font-medium text-gray-800">Platform Expansion</span>
                    <span class="text-green-600 font-bold">$4M</span>
                  </div>
                  <p class="text-gray-600 text-sm">
                    Extend platform capabilities to target GPCRs and ion channels, opening new therapeutic opportunities.
                  </p>
                </div>

                <div class="bg-white border border-gray-200 rounded-lg p-4">
                  <div class="flex justify-between items-center mb-2">
                    <span class="font-medium text-gray-800">Team Building</span>
                    <span class="text-purple-600 font-bold">$4M</span>
                  </div>
                  <p class="text-gray-600 text-sm">
                    Build world-class team in antibody discovery, preclinical development, and regulatory affairs.
                  </p>
                </div>
              </div>
            </div>

            <div>
              <img src="https://kimi-web-img.moonshot.cn/img/images.unsplash.com/e366ba7bc0b710e2669b833e0bb2714d50f6022f" alt="Biotechnology laboratory equipment" class="rounded-lg shadow-lg w-full h-64 object-cover mb-4" size="medium" aspect="wide" style="photo" query="biotechnology laboratory equipment" referrerpolicy="no-referrer" data-modified="1" data-score="0.00"/>

              <div class="bg-gray-50 p-4 rounded-lg">
                <h4 class="font-semibold text-gray-800 mb-3">Investment Highlights</h4>
                <ul class="space-y-2 text-gray-700 text-sm">
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-star text-yellow-500"></i>
                    <span>Proprietary platform with 20+ successful campaigns</span>
                  </li>
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-star text-yellow-500"></i>
                    <span>Strategic partnerships with 92Bio and Moderna</span>
                  </li>
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-star text-yellow-500"></i>
                    <span>Clear path to IND filing within 24 months</span>
                  </li>
                  <li class="flex items-center space-x-2">
                    <i class="fas fa-star text-yellow-500"></i>
                    <span>$2.5B addressable market opportunity</span>
                  </li>
                </ul>
              </div>
            </div>
          </div>

          <div class="text-center">
            <p class="text-lg text-gray-700 mb-4">
              This funding will transform Leveragen from a validated platform company into a clinical-stage biotechnology leader, positioning us to capture significant market share in the rapidly expanding single-domain antibody market.
            </p>
            <div class="bg-blue-50 p-4 rounded-lg inline-block">
              <div class="text-2xl font-bold text-blue-700">$500M+</div>
              <div class="text-sm text-blue-600">Projected market opportunity capture by 2030</div>
            </div>
          </div>
        </div>
      </section>

      <div class="section-divider"></div>

      <!-- Team and Vision -->
      <section id="team" class="px-8 py-16 max-w-6xl mx-auto">
        <h2 class="serif text-4xl font-bold text-gray-900 mb-8">The Leveragen Team and Vision</h2>

        <div class="grid lg:grid-cols-2 gap-8 mb-12">
          <div class="space-y-6">
            <h3 class="serif text-2xl font-semibold text-gray-800">Leadership with Deep Expertise</h3>
            <p class="text-lg text-gray-700">
              Leveragen is led by seasoned professionals with proven track records in antibody engineering, drug development, and business management spanning the entire pharmaceutical value chain.
            </p>

            <div class="bg-gradient-to-r from-blue-50 to-indigo-50 p-6 rounded-xl">
              <h4 class="font-semibold text-gray-800 mb-4">Team Capabilities</h4>
              <div class="grid grid-cols-2 gap-4 text-sm">
                <div>
                  <strong class="text-gray-800">Scientific Expertise</strong>
                  <ul class="text-gray-600 mt-2 space-y-1">
                    <li>• Antibody engineering</li>
                    <li>• CRISPR gene editing</li>
                    <li>• Protein biochemistry</li>
                    <li>• Immunology</li>
                  </ul>
                </div>
                <div>
                  <strong class="text-gray-800">Development Experience</strong>
                  <ul class="text-gray-600 mt-2 space-y-1">
                    <li>• Preclinical development</li>
                    <li>• Regulatory affairs</li>
                    <li>• Clinical trial design</li>
                    <li>• Manufacturing scale-up</li>
                  </ul>
                </div>
              </div>
            </div>
          </div>

          <div>
            <img src="https://kimi-web-img.moonshot.cn/img/www.amgenbiotechexperience.com/06de10d042fa30893b2f84f7b23712501f507cbb.png" alt="Biotechnology research team working in laboratory" class="rounded-lg shadow-lg w-full h-64 object-cover" size="medium" aspect="wide" style="photo" query="biotechnology research team laboratory" referrerpolicy="no-referrer" data-modified="1" data-score="0.00"/>
          </div>
        </div>

        <div class="text-center mb-12">
          <h3 class="serif text-3xl font-bold text-gray-900 mb-4">Our Vision: Redefining the Standard</h3>
          <div class="pull-quote text-center border-none pl-0 text-xl">
            &#34;To transform antibody therapeutics by providing a reliable, scalable, and de-risked platform that unlocks the full potential of single-domain antibodies for patients worldwide.&#34;
          </div>
        </div>

        <div class="bg-gradient-to-br from-gray-900 to-blue-900 text-white p-12 rounded-2xl text-center">
          <h3 class="serif text-3xl font-bold mb-6">Join Us in Building the Next Generation of Human Medicines</h3>
          <p class="text-xl opacity-90 mb-8 max-w-3xl mx-auto">
            Leveragen is at a critical inflection point. With our proprietary platform, strategic partnerships, and clear path to clinical development, we are positioned to capture significant value in the $2.5B single-domain antibody market.
          </p>

          <div class="grid md:grid-cols-3 gap-6 mb-8">
            <div class="bg-white/10 p-6 rounded-lg">
              <div class="text-2xl font-bold mb-2">$15M</div>
              <div class="text-sm opacity-80">Series A Investment</div>
            </div>
            <div class="bg-white/10 p-6 rounded-lg">
              <div class="text-2xl font-bold mb-2">24 Months</div>
              <div class="text-sm opacity-80">To IND Filing</div>
            </div>
            <div class="bg-white/10 p-6 rounded-lg">
              <div class="text-2xl font-bold mb-2">$2.5B</div>
              <div class="text-sm opacity-80">Addressable Market</div>
            </div>
          </div>

          <button class="bg-white text-gray-900 px-12 py-4 rounded-lg font-semibold text-lg hover:bg-gray-100 transition-colors">
            Contact Us to Learn More
          </button>
        </div>
      </section>

      <!-- Footer -->
      <footer class="bg-gray-50 px-8 py-12 border-t border-gray-200">
        <div class="max-w-6xl mx-auto text-center">
          <div class="mb-8">
            <h3 class="serif text-2xl font-bold text-gray-900 mb-4">Leveragen</h3>
            <p class="text-gray-600 max-w-2xl mx-auto">
              Pioneering the next generation of fully human single-domain antibody therapeutics to transform patient care worldwide.
            </p>
          </div>

          <div class="grid md:grid-cols-3 gap-8 mb-8">
            <div>
              <h4 class="font-semibold text-gray-800 mb-3">Contact</h4>
              <p class="text-gray-600 text-sm">
                For investment inquiries and partnership opportunities
              </p>
            </div>
            <div>
              <h4 class="font-semibold text-gray-800 mb-3">Location</h4>
              <p class="text-gray-600 text-sm">
                Biotechnology research hub with state-of-the-art facilities
              </p>
            </div>
            <div>
              <h4 class="font-semibold text-gray-800 mb-3">Connect</h4>
              <p class="text-gray-600 text-sm">
                Follow our progress in revolutionizing antibody therapeutics
              </p>
            </div>
          </div>

          <div class="text-sm text-gray-500">
            <p>© 2025 Leveragen. All rights reserved. | Confidential Investment Presentation</p>
          </div>
        </div>
      </footer>
    </main>

    <script>
        // Initialize Mermaid with enhanced styling for better contrast
        mermaid.initialize({
            startOnLoad: true,
            theme: 'base',
            themeVariables: {
                primaryColor: '#ffffff',
                primaryTextColor: '#1a1a1a',
                primaryBorderColor: '#2d5a87',
                lineColor: '#4a90a4',
                sectionBkgColor: '#f8fafb',
                altSectionBkgColor: '#ffffff',
                gridColor: '#e5e7eb',
                secondaryColor: '#f0f9ff',
                tertiaryColor: '#f8fafb',
                background: '#ffffff',
                mainBkg: '#ffffff',
                secondBkg: '#f8fafb',
                tertiaryBkg: '#f0f9ff',
                edgeLabelBackground: '#ffffff',
                clusterBkg: '#f8fafb',
                clusterBorder: '#4a90a4',
                defaultLinkColor: '#4a90a4',
                titleColor: '#1a1a1a',
                darkMode: false,
                // Enhanced contrast for different node types
                cScale0: '#ffebee',
                cScale1: '#fff3e0', 
                cScale2: '#e8f5e8',
                cScale3: '#f8fafb',
                cScale4: '#f0f9ff',
                // Text colors for better contrast
                cScaleLabel0: '#1a1a1a',
                cScaleLabel1: '#1a1a1a',
                cScaleLabel2: '#1a1a1a',
                cScaleLabel3: '#1a1a1a',
                cScaleLabel4: '#1a1a1a'
            },
            flowchart: {
                useMaxWidth: false,
                htmlLabels: true,
                curve: 'basis',
                padding: 30,
                nodeSpacing: 50,
                rankSpacing: 80,
                diagramPadding: 20
            },
            fontSize: 14,
            fontFamily: 'Inter, sans-serif'
        });

        // Initialize Mermaid Controls for zoom and pan
        function initializeMermaidControls() {
            const containers = document.querySelectorAll('.mermaid-container');

            containers.forEach(container => {
            const mermaidElement = container.querySelector('.mermaid');
            let scale = 1;
            let isDragging = false;
            let startX, startY, translateX = 0, translateY = 0;

            // 触摸相关状态
            let isTouch = false;
            let touchStartTime = 0;
            let initialDistance = 0;
            let initialScale = 1;
            let isPinching = false;

            // Zoom controls
            const zoomInBtn = container.querySelector('.zoom-in');
            const zoomOutBtn = container.querySelector('.zoom-out');
            const resetBtn = container.querySelector('.reset-zoom');
            const fullscreenBtn = container.querySelector('.fullscreen');

            function updateTransform() {
                mermaidElement.style.transform = `translate(${translateX}px, ${translateY}px) scale(${scale})`;

                if (scale > 1) {
                container.classList.add('zoomed');
                } else {
                container.classList.remove('zoomed');
                }

                mermaidElement.style.cursor = isDragging ? 'grabbing' : 'grab';
            }

            if (zoomInBtn) {
                zoomInBtn.addEventListener('click', () => {
                scale = Math.min(scale * 1.25, 4);
                updateTransform();
                });
            }

            if (zoomOutBtn) {
                zoomOutBtn.addEventListener('click', () => {
                scale = Math.max(scale / 1.25, 0.3);
                if (scale <= 1) {
                    translateX = 0;
                    translateY = 0;
                }
                updateTransform();
                });
            }

            if (resetBtn) {
                resetBtn.addEventListener('click', () => {
                scale = 1;
                translateX = 0;
                translateY = 0;
                updateTransform();
                });
            }

            if (fullscreenBtn) {
                fullscreenBtn.addEventListener('click', () => {
                if (container.requestFullscreen) {
                    container.requestFullscreen();
                } else if (container.webkitRequestFullscreen) {
                    container.webkitRequestFullscreen();
                } else if (container.msRequestFullscreen) {
                    container.msRequestFullscreen();
                }
                });
            }

            // Mouse Events
            mermaidElement.addEventListener('mousedown', (e) => {
                if (isTouch) return; // 如果是触摸设备，忽略鼠标事件

                isDragging = true;
                startX = e.clientX - translateX;
                startY = e.clientY - translateY;
                mermaidElement.style.cursor = 'grabbing';
                updateTransform();
                e.preventDefault();
            });

            document.addEventListener('mousemove', (e) => {
                if (isDragging && !isTouch) {
                translateX = e.clientX - startX;
                translateY = e.clientY - startY;
                updateTransform();
                }
            });

            document.addEventListener('mouseup', () => {
                if (isDragging && !isTouch) {
                isDragging = false;
                mermaidElement.style.cursor = 'grab';
                updateTransform();
                }
            });

            document.addEventListener('mouseleave', () => {
                if (isDragging && !isTouch) {
                isDragging = false;
                mermaidElement.style.cursor = 'grab';
                updateTransform();
                }
            });

            // 获取两点之间的距离
            function getTouchDistance(touch1, touch2) {
                return Math.hypot(
                touch2.clientX - touch1.clientX,
                touch2.clientY - touch1.clientY
                );
            }

            // Touch Events - 触摸事件处理
            mermaidElement.addEventListener('touchstart', (e) => {
                isTouch = true;
                touchStartTime = Date.now();

                if (e.touches.length === 1) {
                // 单指拖动
                isPinching = false;
                isDragging = true;

                const touch = e.touches[0];
                startX = touch.clientX - translateX;
                startY = touch.clientY - translateY;

                } else if (e.touches.length === 2) {
                // 双指缩放
                isPinching = true;
                isDragging = false;

                const touch1 = e.touches[0];
                const touch2 = e.touches[1];
                initialDistance = getTouchDistance(touch1, touch2);
                initialScale = scale;
                }

                e.preventDefault();
            }, { passive: false });

            mermaidElement.addEventListener('touchmove', (e) => {
                if (e.touches.length === 1 && isDragging && !isPinching) {
                // 单指拖动
                const touch = e.touches[0];
                translateX = touch.clientX - startX;
                translateY = touch.clientY - startY;
                updateTransform();

                } else if (e.touches.length === 2 && isPinching) {
                // 双指缩放
                const touch1 = e.touches[0];
                const touch2 = e.touches[1];
                const currentDistance = getTouchDistance(touch1, touch2);

                if (initialDistance > 0) {
                    const newScale = Math.min(Math.max(
                    initialScale * (currentDistance / initialDistance),
                    0.3
                    ), 4);
                    scale = newScale;
                    updateTransform();
                }
                }

                e.preventDefault();
            }, { passive: false });

            mermaidElement.addEventListener('touchend', (e) => {
                // 重置状态
                if (e.touches.length === 0) {
                isDragging = false;
                isPinching = false;
                initialDistance = 0;

                // 延迟重置isTouch，避免鼠标事件立即触发
                setTimeout(() => {
                    isTouch = false;
                }, 100);
                } else if (e.touches.length === 1 && isPinching) {
                // 从双指变为单指，切换为拖动模式
                isPinching = false;
                isDragging = true;

                const touch = e.touches[0];
                startX = touch.clientX - translateX;
                startY = touch.clientY - translateY;
                }

                updateTransform();
            });

            mermaidElement.addEventListener('touchcancel', (e) => {
                isDragging = false;
                isPinching = false;
                initialDistance = 0;

                setTimeout(() => {
                isTouch = false;
                }, 100);

                updateTransform();
            });

            // Enhanced wheel zoom with better center point handling
            container.addEventListener('wheel', (e) => {
                e.preventDefault();
                const rect = container.getBoundingClientRect();
                const centerX = rect.width / 2;
                const centerY = rect.height / 2;

                const delta = e.deltaY > 0 ? 0.9 : 1.1;
                const newScale = Math.min(Math.max(scale * delta, 0.3), 4);

                // Adjust translation to zoom towards center
                if (newScale !== scale) {
                const scaleDiff = newScale / scale;
                translateX = translateX * scaleDiff;
                translateY = translateY * scaleDiff;
                scale = newScale;

                if (scale <= 1) {
                    translateX = 0;
                    translateY = 0;
                }

                updateTransform();
                }
            });

            // Initialize display
            updateTransform();
            });
        }

        // Initialize after mermaid renders
        setTimeout(initializeMermaidControls, 1000);

        // Smooth scrolling for anchor links
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    target.scrollIntoView({
                        behavior: 'smooth',
                        block: 'start'
                    });
                }
            });
        });

        // Highlight current section in TOC
        window.addEventListener('scroll', () => {
            const sections = document.querySelectorAll('section[id], div[id]');
            const scrollPos = window.scrollY + 200;
            
            sections.forEach(section => {
                const top = section.offsetTop;
                const bottom = top + section.offsetHeight;
                const id = section.getAttribute('id');
                const tocLink = document.querySelector(`a[href="#${id}"]`);
                
                if (scrollPos >= top && scrollPos <= bottom) {
                    document.querySelectorAll('.toc-fixed a').forEach(link => {
                        link.classList.remove('text-blue-600', 'font-semibold');
                        link.classList.add('text-gray-600');
                    });
                    if (tocLink) {
                        tocLink.classList.remove('text-gray-600');
                        tocLink.classList.add('text-blue-600', 'font-semibold');
                    }
                }
            });
        });
    </script>
  

</body></html>